Avillion Advances Co-development Programme with Merck

Avillion has advanced its co-development programme with Merck and an IND is now open for a Phase 2 Study of M1095, an anti-IL-17 A/F Nanobody® in psoriasis.

Please read the full press release here.

TwitterLinkedInEmailPrint